Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6610736 | 0.87 | MAPK14 (0.61) | MAPK14CCNA2CDK2CSNK1ECDK5 | |
| SCHEMBL6790904 | 0.83 | MAPK14 (0.64) | MAPK14CCNA2CDK2CSNK1ECDK5 | |
| SCHEMBL6624696 | 0.82 | MAPK14 (0.57) | MAPK14SCN9A | |
| SCHEMBL6775564 | 0.81 | MAPK14 (0.56) | MAPK14PIK3CA | |
| SCHEMBL6781430 | 0.81 | MAPK14 (0.56) | MAPK14CDK2MAPK13MAPK12MAPK11 | |
| SCHEMBL6608972 | 0.81 | MAPK14 (0.56) | MAPK14CDK2MAPK13MAPK12MAPK11 | |
| SCHEMBL6772997 | 0.80 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11SCN9A | |
| SCHEMBL6608979 | 0.80 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6779673 | 0.80 | MAPK14 (0.62) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL6613247 | 0.79 | MAPK14 (0.61) | MAPK14CCNA2CDK2CSNK1ECDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-01-16 | — | — | US | claimed |
| US-6727364-B2 | ANTIINFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | IL4, IL1A, IL2 | MAPK14 3429/4885CCNA2 2779/4885CDK2 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.